News -

Latest addition to Euro Diagnostica’s portfolio of iLite™ Assay Ready Cells within inflammation: iLite™ GM-CSF Assay Ready Cells!

Anti-inflammatory drugs are commonly used to treat inflammation and autoimmune diseases, they help manage chronic pain, inflammation, and swelling.

The growth factor GM-CSF (Granulocyte-macrophage colony stimulating factor) has shown to be a key player in inflammation and autoimmunity. The inhibition of GM-CSF is an attractive approach for the treatment of these diseases and has proven to have a much broader range of biological activities in both innate and adaptive immune responses.

As elevated GM-CSF levels can be seen in synovial fluid and blood from patients with inflammatory disorders. Assay Ready Cells targeting GM-CSF have been developed by Euro Diagnostica (Biomonitor) and are expected to be a useful tool in the drug development process for treatment of inflammatory and autoimmune diseases.

The iLite™ GM-CSF Assay Ready Cells express luciferase under the control of a GM-CSF responsive promoter. When stimulating the cells with GM-CSF the resulting luminescent signal is proportional to the functional activity of GM-CSF in the sample. The cells can therefore be utilized as a highly sensitive assay for quantification of GM-CSF functional activity, GM-CSF inhibitor activity or neutralizing antibodies against GM-CSF in test samples, including human serum.

To learn more about iLite™ GM-CSF Assay Ready Cells click here.

Related links

Topics

  • Diseases

Categories

  • product
  • ilite cell-based assays

Contacts

Trine Österbye

VP Biopharma Solutions iLite Cell-based Assays +46 40 53 76 47

Related content

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.